-
1.发明公开公开(公告)号：US20240339176A1
公开(公告)日：2024-10-10
申请号：US18630510
申请日：2024-04-09
摘要： Disclosed are systems, means and compositions of matter utilizing artificial intelligence to create unique cells and/or organs from pluripotent stem cells. In one embodiment an artificial intelligence/machine learning approach is utilized to overview and categorize molecular and cellular data regarding normal embryonic development and associated pathways. Through acquiring this information, said artificial intelligence/machine learning system develops a graded list of morphogens/differentiating agents and/or conditions that are utilized to replicate the process of cell/tissue/organ formation artificially. In one embodiment the invention teaches generation of artificial pancreatic organoids through growth factors predicted by said artificial intelligence/machine learning systems. In other embodiments embryogenesis is recapitulated in adult tissue using predicted morphogens and/or extracellular matrix treatments.
-
公开(公告)号：US20230302105A1
公开(公告)日：2023-09-28
申请号：US17931868
申请日：2022-09-13
发明人： Thomas Ichim , Amit Patel
IPC分类号： A61K39/00 , A61K35/28 , C12N5/0775
CPC分类号： A61K39/0008 , A61K35/28 , C12N5/0665 , A61K2039/577 , C12N2502/137 , A61K2039/5158
摘要： Described are antigen specific and antigen non-specific means of suppressing development of Type 1 Diabetes in a mammal through administration of exosomes, microvesicles or apoptotic bodies from monocytic lineage cells that have been reprogrammed by contact with mesenchymal stem cells and/or mesenchymal stem cell conditioned media. In one embodiment, the invention provides administration of exosomes that have been generated from monocytic cells that have been loaded with tolerogenic antigens and/or epitopes. In another embodiment the invention provides administration of allogeneic myeloid derived exosomes that are loaded with tolerogenic antigens. In another embodiment the invention provides means of stimulating exosome release in vivo from allogeneic cells that have been administered to the patient in need of treatment.
-
公开(公告)号：US20220202861A1
公开(公告)日：2022-06-30
申请号：US17559985
申请日：2021-12-22
发明人： Thomas Ichim , Amit Patel , Timothy Warbington
IPC分类号： A61K35/17 , A61P1/16 , C12N5/0735
摘要： Disclosed are methods, means and compositions of matter useful for treatment of liver failure using ex vivo reprogrammed immune cells. In one embodiment, cells of the recipient (autologous) are cocultured with a regenerative cell population alone or in the presence of one or more adjuvants. Said adjuvants enhance transfer of regenerative activity from said mesenchymal stem cells to said immune cells. In one embodiment said ex vivo reprogrammed immune cells are capable of inducing death or inactivation of hepatic stellate cells. In other embodiments, said immune cells provide antifibrotic activity to induce suppression of liver cirrhosis. In other embodiments, said immune cells provide for growth factors to enhance hepatic regeneration.
-
公开(公告)号：US20220175835A1
公开(公告)日：2022-06-09
申请号：US17546469
申请日：2021-12-09
发明人： Thomas Ichim , Amit Patel
IPC分类号： A61K35/17 , A61K35/15 , C12N5/0784 , A61P37/00
摘要： Disclosed are means, methods and compositions of matter useful for inhibiting, in an antigen-specific manner, immunity towards an autoantigen or alloantigen. In one embodiment of the invention, regenerative cells are cultured ex vivo together with immune cells from a mammal suffering from an autoimmune condition. Autoantigens or alloantigens are added in the culture of regenerative cells and cells from an autoimmune disease suffering individual in a manner so that said regenerative cells can endow onto said immune cells of said patient suffering from autoimmunity a state of antigen specific infectious tolerance. In one embodiment, said infectious tolerance involves T regulatory cells inducing conversion of dendritic cells to tolerogeneic dendritic cells, and furthermore in other embodiments administration of tolerogenic dendritic cells induces T regulatory cells.
-
5.发明申请公开(公告)号：US20180015127A1
公开(公告)日：2018-01-18
申请号：US15652213
申请日：2017-07-17
发明人： Thomas Ichim , Amit Patel
CPC分类号： A61K35/44 , A61K9/0019 , A61K31/565 , A61K31/57 , A61K35/17 , A61K35/22 , A61K35/28 , A61K35/51 , A61K45/06 , A61K2035/124 , C12N5/0662 , C12N5/0663 , C12N5/0692 , C12N2320/30 , C12N2501/392 , A61K2300/00
摘要： This invention pertains to the field of ovarian aging and premature ovarian failure. Specifically, we herein disclose methods for treating these conditions using endothelial progenitor cells alone or in combination with mesenchymal stem cells. Furthermore, these cell-based therapies can be utilized in combination with estrogen and progesterone receptor ligands to enhance the therapeutic activity of said cells for restoring or maintaining ovarian function and female fertility
-
公开(公告)号：US20240331809A1
公开(公告)日：2024-10-03
申请号：US18623197
申请日：2024-04-01
CPC分类号： G16C20/10 , G01N33/5055 , G16B20/50 , G16C20/70 , G01N2333/4716
摘要： Disclosed are methods, means and systems of identifying compounds and augment T regulatory cell activity and/or number in vitro and/or in vivo utilizing deep learning approaches. Systems for screening compound libraries in silico are provided as well as laboratory methods of testing modulation of T regulatory cell activity and/or numbers. Results provided by the disclosure will serve as the basis for increasing T regulatory cells, which is desirable in situations of autoimmunity or organ transplantation. In situations of oncology or infectious disease reduction of T regulatory cell number and/or activity is desired.
-
公开(公告)号：US20220202860A1
公开(公告)日：2022-06-30
申请号：US17559970
申请日：2021-12-22
发明人： Thomas Ichim , Amit Patel
IPC分类号： A61K35/17 , C12N5/0783 , A61P9/04
摘要： Disclosed are methods, means and compositions of matter useful for treatment of heart failure, and/or post infarct pathological remodeling using ex vivo reprogrammed immune cells. In one embodiment, cells of the recipient (autologous) are cocultured with a regenerative cell population alone or in the presence of one or more adjuvants. Said adjuvants enhance transfer of regenerative activity from said mesenchymal stem cells to said immune cells. In one embodiment said ex vivo reprogrammed immune cells are capable of inducing death or inactivation of cardiac fibrotic cells. In other embodiments, said immune cells provide antifibrotic activity to induce suppression of cardiac fibrosis. In other embodiments, said immune cells provide for growth factors to enhance cardiac regeneration.
-
8.发明申请公开(公告)号：US20180085405A1
公开(公告)日：2018-03-29
申请号：US15717810
申请日：2017-09-27
发明人： Thomas Ichim , Amit Patel , Santosh Kesari
IPC分类号： A61K35/50
CPC分类号： A61K35/50 , A61K35/545 , C12N2502/03
摘要： Disclosed are compositions of matter useful for treatment of stroke derived from amniotic fluid stem cell produced factors. In one embodiment the invention teaches the use of products derived from amniotic fluid stem cells cultured under basal conditions. In another embodiment the invention teaches the utilization of amniotic stem cell derived products from said amniotic stem cells cultured under conditions of stress. Said amniotic stem cell derived products include small molecules, proteins, peptides, conditioned media, microvesicles, including exosomes and apoptotic bodies. In one embodiment, the invention teaches administration of amniotic fluid stem cells that have been exposed to a stress condition.
-
9.发明申请公开(公告)号：US20170354686A1
公开(公告)日：2017-12-14
申请号：US15617813
申请日：2017-06-08
发明人： Thomas Ichim , Amit Patel
IPC分类号： A61K35/28 , C12N5/0775
CPC分类号： A61K35/28 , A61K35/35 , C12N5/0667 , C12N2500/84 , G01N33/50
摘要： Disclosed are means of treating spontaneous abortion utilizing cellular populations derived from autologous adipose tissue. In one embodiment the invention teaches the collection of stromal vascular fraction from women attempting to conceive, isolation of anti-abortigenic cells from said stromal vascular fraction, storing said cells, and administering said cells in early pregnancy or when conception is desired.
-
10.发明授权公开(公告)号：US11795433B2
公开(公告)日：2023-10-24
申请号：US15987739
申请日：2018-05-23
发明人： Thomas Ichim , Amit Patel
CPC分类号： C12N5/0605 , C12N5/0634 , C12N2501/01 , C12N2501/115 , C12N2501/13 , C12N2501/2302 , C12N2502/025 , C12N2502/11 , C12N2533/50
摘要： Disclosed are means, methods, and compositions of matter useful for treatment of neuroinflammation, autoimmunity, transplant rejection, or graft versus host disease (GVHD) comprising exposing autologous immune cells to allogeneic amniotic fluid derived stem cells. In one embodiment peripheral blood mononuclear cells are cultured in the presence of amniotic fluid stem cells in the presence of interleukin-2 for a period of time sufficient to endow tolerogenic properties. Said tolerogenic properties include ability to suppress adaptive or innate immune responses. In another embodiment the invention provides methods of generating antigen specific immune regulatory cells by culture of lymphocytes together with amniotic fluid stem cells in the presence of antigen to which specific immune regulation is desired.
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.022 秒)
